Post by siTOOLs Biotech GmbH

We’re excited to be at GASL 2026 in Freiburg this week and to share something we haven’t officially announced before. Leveraging experience from multiple customer projects, we now formally offer early-stage development support for the development of therapeutic GalNAc–siRNA targeting the liver. Our support spans the full development path, from target identification and validation through siRNA screening, optimization, and in vivo testing. At the conference, we’ll be showcasing our approach to therapeutic siRNA development and look forward to exchanging ideas with researchers interested in moving targets genes toward siRNA-based therapeutics. Stop by our booth to connect. Looking forward to inspiring discussions and new collaborations! #GASL #GASL2026 #siTOOLs #siRNA #siRNATherapeutics #Liverdisease #GalNAc #Freiburg